Article on classification of GISTs by array CGH published in "Cancer Research"
L. Meza-Zepeda
Histologically related connective tissue tumors, leiomyosarcomas (LMSs) and gastrointestinal stromal tumors (GISTs), were until recently diagnosed as one tumor type. Leonardo Meza-Zepeda et al has shown that that the patterns of genome copy-number aberrations reflect the underlying biology of the tumors. These important findings were recently published in the well reputed journal "Cancer Research" (impact factor 7,6). Meza-Zepeda is working as a post doc in Ola Myklebost's group at the Department of Tumor Biology.
By global array CGH analysis they could, without supervision, separate completely the two tumor types. Because GISTs are sensitive to specific tyrosinase inhibitors, this may indicate clinical utility for array CGH to assist in this clinically important distinction.
From major journals, first or last author from the Institute for Cancer Research
Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B(2025) Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes Commun Biol, 8(1), 992 DOI 10.1038/s42003-025-08413-0, PubMed 40610675
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature, 642(8069), 877-888 DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA(2025) Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis J Transl Med, 23(1), 672 DOI 10.1186/s12967-025-06644-7, PubMed 40528241
Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B(2025) Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes Commun Biol, 8(1), 992 DOI 10.1038/s42003-025-08413-0, PubMed 40610675
Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C(2025) Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Pharmacoepidemiol Drug Saf, 34(7), e70181 DOI 10.1002/pds.70181, PubMed 40552731
Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH(2025) Elevated KRAS protein level is associated with better survival in pancreatic cancer BMC Cancer, 25(1), 1080 DOI 10.1186/s12885-025-14461-w, PubMed 40596921